BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

The Company's DIS business provides insights through clinical testing and related services to patients, physicians, hospitals, ACOs, IDNs, health plans, employers and others. The Company is the world's leading provider of diagnostic information services, which includes providing clinical testing services such as routine (including drugs-of-abuse) testing, gene-based and esoteric testing, and anatomic pathology services, as well as related services and insights. The DIS business accounted for greater than 90% of net revenues in 2016 and 2015.

All other operating segments include the Company's DS businesses, which consists of its risk assessment services, diagnostic products (see Note 6 regarding the planned disposition of Focus Diagnostics), healthcare information technology and clinical trials testing (prior to July 1, 2015) businesses. The Company's DS businesses offer a variety of solutions for life insurers, healthcare providers and others.

In addition to the planned disposition of Focus Diagnostics, the Company is winding down its Celera Products business, which did not have a material impact on the Company's consolidated financial statements.

At March 31, 2016, substantially all of the Company’s services are provided within the United States, and substantially all of the Company’s assets are located within the United States.

The following table is a summary of segment information for the three months ended March 31, 2016 and 2015. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the consolidated financial statements contained in the Company’s 2015 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.

	Three Months Ended March 31,
	2016			2015
Net revenues:
DIS business	$	1,756		$	1,692
All other operating segments	107			147
Total net revenues	$	1,863		$	1,839
Operating earnings (loss):
DIS business	$	278		$	242
All other operating segments	21			26
General corporate activities	(42		)	(40		)
Total operating income	257			228
Non-operating expenses, net	(85		)	(123		)
Income before income taxes and equity in earnings of equity method investees	172			105
Income tax expense	(68		)	(42		)
Equity in earnings of equity method investees, net of taxes	10			7
Net income	114			70
Less: Net income attributable to noncontrolling interests	12			9
Net income attributable to Quest Diagnostics	$	102		$	61